The current study expanded upon previously reported behavioral differences between AD and non-AD mice [19] by utilizing a more advanced stage of AD (12 months vs. 6 months of age), and assessing BDNF-mediated effects of rTMS as a treatment of AD. The gene discussed is BDNF; the disease is Alzheimer disease.